PSS21 Gap Analysis for Patient-Reported Outcomes Measures for Alopecia

    May 2011 in “ Value in Health ”
    Brooke Dennee-Sommers, N. Galipeau, Kristina Fitzgerald, Catherine J Evans, Stephen D. Daniels, Burgess S
    Image of study
    TLDR No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
    The document presents a gap analysis aimed at identifying a suitable patient-reported outcome (PRO) measure for treatments in alopecia. The search across MEDLINE®, PROQOLID, and PROLabels databases resulted in 45 instruments, of which 23 were patient-reported, 17 were investigator-rated, three were devices, and two were objective hair measures. After applying exclusion criteria, 41 instruments were discarded, leaving four for further consideration: the Kingsley Alopecia Questionnaire (KAP), the Hair Growth Questionnaire, the Hair Problem List, and the Women's Androgenic Alopecia Quality of Life Questionnaire (WAA-QOL). However, none of these instruments fully met the FDA's PRO Guidance requirements. The Hair Growth Questionnaire, developed based on male input only, could potentially be revised for relevance to women with alopecia. The Hair Problem List and the WAA-QOL might be supplemented to include more concepts of interest and tested for relevance to both men and women with alopecia.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 1 year ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community KX-826: Long-Term Safety Results are out!

      in Research/Science  162 upvotes 10 months ago
      KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

      community Disappointing news on Breezula/CB-03-01

       22 upvotes 6 years ago
      The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

    Related Research

    2 / 2 results